Holen Sie sich die Stockscreener-App
23.56
2.88%
0.66
Schlusskurs vom Vortag:
$22.90
Offen:
$23.04
24-Stunden-Volumen:
1.35M
Relative Volume:
0.67
Marktkapitalisierung:
$3.99B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
130.89
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-1.92%
1M Leistung:
+10.77%
6M Leistung:
+7.83%
1J Leistung:
+45.61%
1-Tages-Spanne:
$22.84
$23.98
1-Wochen-Bereich:
$22.81
$24.50
52-Wochen-Spanne:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.56 | 3.87B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
How ACADIA Pharmaceuticals Inc. stock trades before earningsInsider Buying & Real-Time Market Trend Scan - newser.com
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - BioSpace
Is ACADIA Pharmaceuticals Inc. stock oversold or undervalued2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 - openPR.com
Will ACADIA Pharmaceuticals Inc. stock split again soonShare Buyback & Verified Entry Point Detection - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Will ACADIA Pharmaceuticals Inc. stock attract more institutional investorsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
ACADIA Pharmaceuticals (ACAD): JP Morgan Lowers Price Target to $31.00 | ACAD Stock News - GuruFocus
Acadia Eyes Record-Breaking Revenue In 2025 With Nuplazid And Daybue - RTTNews
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights - MSN
(ACAD) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - Yahoo Finance
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - sharewise.com
Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals! - TipRanks
Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com - Investing.com Australia
Insider Sell: James Daly Sells 30,000 Shares of ACADIA Pharmaceu - GuruFocus
Acadia Pharmaceuticals director Daly sells $670k in stock - Investing.com
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersEarnings Summary Report & Daily Stock Momentum Reports - newser.com
Acadia Pharmaceuticals stock price target lowered by RBC on weak Medicaid volume - Investing.com Australia
What drives ACADIA Pharmaceuticals Inc stock priceVolatility Trading Techniques & Free Explosive Earning Power - earlytimes.in
Positive readouts validate pipelines, fuel drug developer rally - BioWorld MedTech
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):